| Literature DB >> 30898177 |
Melanie Lean1, Miriam Fornells-Ambrojo2, Alyssa Milton3, Brynmor Lloyd-Evans4, Bronwyn Harrison-Stewart5, Amina Yesufu-Udechuku6, Tim Kendall7, Sonia Johnson8.
Abstract
BACKGROUND: Self-management is intended to empower individuals in their recovery by providing the skills and confidence they need to take active steps in recognising and managing their own health problems. Evidence supports such interventions in a range of long-term physical health conditions, but a recent systematic synthesis is not available for people with severe mental health problems.AimsTo evaluate the effectiveness of self-management interventions for adults with severe mental illness (SMI).Entities:
Keywords: Schizophrenia; bipolar affective disorders; community mental health teams; psychosocial interventions; psychotic disorders
Mesh:
Year: 2019 PMID: 30898177 PMCID: PMC6499726 DOI: 10.1192/bjp.2019.54
Source DB: PubMed Journal: Br J Psychiatry ISSN: 0007-1250 Impact factor: 9.319
Fig. 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flow chart.
Fig. 2Cochrane Risk of Bias Summary.
Analysis of self-management intervention for people with severe mental illness compared with control (active or treatment as usual) (random-effects model)
| Outcome | Time of data collection | Trials ( | Participants SM/control ( | Estimate | Summary of estimate (95% CI) | Z, | Heterogeneity | |
|---|---|---|---|---|---|---|---|---|
| I2 (%) | ||||||||
| Symptoms | ||||||||
| Total symptoms | End of treatment | 17 | 912/1067 | SMD | −0.43 (−0.63, −0.22) | 4.12, | 78a | |
| Follow-up | 13 | 676/844 | SMD | −0.88 (−1.19, −0.57) | 5.52, | 87a | ||
| Positive symptoms | End of treatment | 8 | 372/507 | SMD | −0.22 (−0.51, 0.07) | 1.50, | 73a | |
| Follow-up | 6 | 312/459 | SMD | −0.61 (−1.03, −0.19) | 2.86, | 85a | ||
| Negative symptoms | End of treatment | 9 | 457/590 | SMD | −0.26 (−0.47, −0.05) | 2.44, | 59a | |
| Follow-up | 7 | 378/523 | SMD | −0.51 (−0.82, −0.21) | 3.28, | 77a | ||
| Affective symptoms (depression/anxiety) | End of treatment | 5 | 230/222 | SMD | −0.26 (−0.51, −0.01) | 2.04, | 40 | |
| Follow-up | 6 | 475/489 | SMD | −0.19 (−0.33, −0.04) | 2.43, | 15 | ||
| Relapse | ||||||||
| Mean number of readmissions to acute care | End of treatment | 5 | 315/456 | SMD | −0.39 (−0.89, 0.11) | 1.52, | 90a | |
| Follow-up | 5 | 257/398 | SMD | −0.92 (−1.63, −0.21) | 2.53, | 93a | ||
| Total number of patients in each group readmitted to acute care | End of treatment | 2 | 104/147 | RR | 0.84 (0.48, 1.46) | 0.63, | Q = 0.72, p = 0.40 | 0 |
| Follow-up | 10 | 416/473 | RR | 0.75 (0.51, 1.08) | 1.54, | 40 | ||
| Length of admission to acute care | End of treatment | 6 | 359/543 | SMD | −0.26 (−0.50, −0.02) | 2.08, | 63a | |
| Follow-up | 7 | 350/558 | SMD | −0.68 (−1.10, −0.25) | 3.12, | 88a | ||
| Recovery | ||||||||
| Total recovery | End of treatment | 11 | 507/506 | SMD | −0.62 (−1.03, −0.22) | 3.03, | 89a | |
| Follow-up | 7 | 543/591 | SMD | −0.81 (−1.40, −0.22) | 2.68, | 94a | ||
| Empowerment | End of treatment | 3 | 187/159 | SMD | −1.44 (−2.97, 0.08) | 1.86, | 96a | |
| Follow-up | 2 | 278/260 | SMD | −0.25 (−0.43, −0.07) | 2.68, | 12 | ||
| Hope | End of treatment | 2 | 200/189 | SMD | −0.18 (−0.38, 0.01) | 1.81, | Q = 0.52, | 0 |
| Follow-up | 3 | 487/480 | SMD | −0.24 (−0.46, −0.02) | 2.16, | 65a | ||
| Self-efficacy | End of treatment | 4 | 322/279 | SMD | −0.38 (−0.62, −0.15) | 3.18, | 45 | |
| Follow-up | 1 | 121/100 | SMD | −0.34 (−0.61, −0.07) | 2.50, | N/A | N/A | |
| Functioning | End of treatment | 15 | 884/1064 | SMD | −0.56 (−0.85, −0.28) | 3.90, | 88a | |
| Follow-up | 14 | 805/1000 | SMD | −0.90 (−1.34, −0.45) | 3.97, | 95a | ||
| Quality of life | End of treatment | 9 | 440/423 | SMD | −0.23 (−0.37, −0.10) | 3.38, | 0 | |
| Follow-up | 7 | 491/489 | SMD | −0.25 (−0.37, −0.12) | 3.84, | 0 | ||
SM, self-management intervention; SMD, standardised mean difference; RR, relative risk.
a. Indicates high heterogeneity: I2 >50% and/or P-value <0.10.
*P < 0.05.